For research use only. Not for use in humans.

Anti-IL-13 (CNTO 607)

Synonyms: il13, NC30

Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD.

Anti-IL-13 (CNTO 607)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD.
References

Product Details

Molecular Weight 144.14
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01355614 COMPLETED Drug: QAX576|Drug: Infliximab Crohn's Disease Novartis Pharmaceuticals 2011-06 PHASE2
NCT01316601 COMPLETED Drug: QAX567 Crohn's Disease Gerhard Rogler 2011-01 PHASE2

(data from https://clinicaltrials.gov, updated on 2017-02-23)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.